

**UNITED STATES DEPARTMENT OF COMMERCE****Patent and Trademark Office**Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

81

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/486,142 03/31/00 MARTINEZ

J 427.034

HM22/1004

CHARLES A MUSERLIAN
BIERMAN MUSERLIAN AND LUCAS
600 THIRD AVENUE
NEW YORK NY 10016

EXAMINER

TAYLOR, J

ART UNIT	PAPER NUMBER
----------	--------------

1656

DATE MAILED:

10/04/00

73

Please find below and/or attached an Office communication concerning this application or proceeding.**Commissioner of Patents and Trademarks**

Office Action Summary	Application No.	Applicant(s)
	09/486,142	MARTINEZ ET AL.
Examiner	Art Unit	
Janell E. Taylor	1656	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).

Status

1) Responsive to communication(s) filed on 01 March 2000.

2a) This action is **FINAL**. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-25 is/are pending in the application.
4a) Of the above claim(s) _____ is/are withdrawn from consideration

5) Claim(s) 11-13 is/are allowed.

6) Claim(s) 1-10, 25 and 145 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claims _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are objected to by the Examiner.

11) The proposed drawing correction filed on _____ is: a) approved b) disapproved.

12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).
a) All b) Some * c) None of the CERTIFIED copies of the priority documents have been:
1. received.
2. received in Application No. (Series Code / Serial Number) ____.
3. received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.

* See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. & 119(e).

Attachment(s)

15) Notice of References Cited (PTO-892) 18) Interview Summary (PTO-413) Paper No(s). _____
16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 19) Notice of Informal Patent Application (PTO-152)
17) Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____. 20) Other: _____

DETAILED ACTION

Claim Rejections - 35 USC § 112

1. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
2. Claims 1-7 and 14-25 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claim 1 recites the phrase "...Y3 and Y4 independently represent a trinucleotide which codes for Arg or Lys..." However, it is not clear if they both code for Arg or Lys, in other words it is possible to have Arg-Arg or Lys-Lys, etc. or if it is possible that together they code for one Arg or Lys. This could be corrected by amending the claim to read "Y3 codes for a trinucleotide representing Arg or Lys, Y4 codes for a trinucleotide coding for Arg or Lys..." Appropriate correction is required.
3. Claims 16-25 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The claims recite the term "DNA bank", however, it is not clear what is meant by this phrase and no clear definition is recited in the specification. This could be clarified by amending the claims to read "DNA sample" which is well known and accepted terminology in the art.
4. Claims 16-25 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The claims recite the phrase "Method for

identification of the precursor..." However; it is not clear what is meant by the word "precursor" in this context. Appropriate correction is required.

Claim Rejections - 35 USC § 102

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

6. Claims 1-10, 16-17, and 20-25 are rejected under 35 U.S.C. 102(e) as being anticipated by Onda et al. (US Patent 5,756,295).

The claims are drawn to a single stranded oligonucleotide OX characterized in that it comprises 9 to 42 nucleotides and is capable of hybridizing under mild or stringent conditions with an oligonucleotide OY of the sequence Y1-Y2-Y3-Y4-Y5, in which Y1 represents a nucleotide sequence of 1 to 12 nucleotides or Y1 is suppressed, Y2 represents a trinucleotide which codes for Gly, Y3 and Y4 independently represent a trinucleotide which codes for Arg or Lys, and Y5 represents a nucleotide sequence of 1 to 21 nucleotides in length or is suppressed. Further embodiments include Y5 representing a nucleotide sequence Y6-Y7-Y8-Y9, in which Y6 represents a trinucleotide which codes for Ser, Thr, or Tyr, Y7 represents a trinucleotide which codes for any amino acid, Y8 represents a trinucleotide which codes for Glu or Asp and Y9 represents a nucleotide sequence comprising 1 to 12 nucleotides. Other claims, such as 16-17 and 20-25, are drawn to a method for identification of the precursor of a

peptide having an amidated C-terminal end, characterized in the following successive stages: obtaining a DNA bank; hybridization of one or more oligonucleotides according to any one of claims 1-7 with the said DNA bank; identification of the DNA sequence or sequences of the said bank which hybridizes with an oligonucleotide according to claim 1, identification in this sequence of one or more precursors of peptides with a possible amidated C-terminal end.

Onda et al teach DNA primers each having a nucleotide sequence substantially complementary to a nucleotide sequence which codes for Gly-Lys-Arg, Gly-Lys-Lys, or Gly-Arg-Arg. (Abstract). Onda et al. also teaches that probes or primers of this sequence may be labeled. Onda teaches that "...there are many cases that useful physiologically active substances or precursor thereof lie between two basic amino acid residues (e.g., Lys-Lys, Lys-Arg, etc.) at the N-terminal side and three amino acid residues (e.g. Gly-Lys-Lys, etc) at the C-terminal side. In an embodiment, human endothelian-3 has an amino acid sequence comprising 21 amino acid residues which extend from the 97th to the 117th amino acid residues in the amino acid sequence..." (Col. 13, bridging Col. 14). Onda et al. also teach the use of a DNA library, and states that "...it has been carried out already to screen the DNA fragments from a DNA library by means of PCR..." (Col. 2, lines 45-50).

Since the claims are drawn to the oligonucleotide OX, which hybridizes to OY, even though the exact sequence of OY is not taught, Onda does teach a primer or probe which fits the description of OX: it is 9 sequences in length, it hybridizes to an

oligonucleotide which contains the nucleotides which represents the amino acids Gly-Lys-Lys, Gly-Lys-Arg, etc.

Summary

Claims 1-7 and 14-25 are rejected under 35 U.S.C. 112, second paragraph.

Claims 1-10, 16-17, and 20-25 are rejected under 35 U.S.C. 102(e) as being anticipated by Onda et al. Claims 11-15 and 18-19 are free of the prior art because they teach unique sequences, OZ and OY. Claims 14, 15, and 18-19 are free of the prior art but are rejected for other reasons.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Janell Taylor, whose telephone number is (703) 305-0273.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones, can be reached at (703) 308-1152.


Any inquiries of a general nature relating to this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Papers related to this application may be submitted by facsimile transmission.

Papers should be faxed to Group 1634 via the PTO Fax Center using (703) 305-3014 or 305-4227. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG (November 15, 1989.)

Janell Taylor

September 28, 2000


W. Gary Jones
Supervisory Patent Examiner
Technology Center 1600

9/28/00